We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Valeant Unit to Pay $58 Million to Settle Allegations of Solodyn Pay-for-Delay Scheme
Valeant Unit to Pay $58 Million to Settle Allegations of Solodyn Pay-for-Delay Scheme
A Valeant Pharmaceuticals unit agreed to pay $58 million to settle multi-district litigation that accused it of violating antitrust laws to keep generic versions of Solodyn off the market.